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What Is the Problem in Clinical Application of  
Sentinel Node Concept to Gastric Cancer Surgery? 
Isao Miyashiro
Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
More than ten years have passed since the sentinel node (SN) concept for gastric cancer surgery was first discussed. Less invasive 
modified surgical approaches based on the SN concept have already been put into practice for malignant melanoma and breast cancer, 
however the SN concept is not yet placed in a standard position in gastric cancer surgery even after two multi-institutional prospective 
clinical trials, the Japan Clinical Oncology Group trial (JCOG0302) and the Japanese Society for Sentinel Node Navigation Surgery (SNNS) 
trial. What is the problem in the clinical application of the SN concept to gastric cancer surgery? There is no doubt that we need reliable 
indicator(s) to determine with certainty the absence of metastasis in the lymph nodes in order to avoid unnecessary lymphadenectomy. 
There are several matters of debate in performing the actual procedure, such as the type of tracer, the site of injection, how to detect and 
harvest, how to detect metastases of SNs, and learning period. These issues have to be addressed further to establish the most suitable 
procedure. Novel technologies such as indocyanine green (ICG) fluorescence imaging and one-step nucleic acid amplification (OSNA) 
may overcome the current difficulties. Once we know what the problems are and how to tackle them, we can pursue the goal.
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Introduction
It is more than 10 years since the sentinel node (SN) concept 
for gastric cancer surgery was first discussed.(1,2) However, SN for 
gastric cancer is not yet clinically used universally, although less in-
vasive modified surgical approaches based on the SN concept have 
already been put into practice for malignant melanoma and breast 
cancer.
What is the problem in the clinical application of SN in gastric 
cancer surgery? As a member of the first group to use SN biopsy 
with indocyanine green (ICG) in gastric cancer surgery,(2) I review 
here the current status of SN for gastric cancer surgery and discuss 
these problems. 
The Concept of SN in Gastric Cancer Surgery
Gastrectomy with regional lymphadenectomy is indicated for 
patients with gastric cancer and clinically suspicious lymph node 
(LN) metastases. The procedure is associated with a satisfactory 
long-term outcome. This “standard procedure” is usually con-
ducted even when the primary tumor is small. However, there is 
controversy regarding the application of this procedure for patients 
with T1 gastric cancer because most of these patients are free of 
nodal metastases. In terms of the results, it appears that lymphad-
enectomy is being conducted at far higher rate than necessary in 
these patients. Thus, we need a reliable indicator that confirms the 
absence of LN metastases with high accuracy, in order to exclude 
lymphadenectomy from the surgical procedure used for patients Miyashiro I
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with T1 gastric cancer and preserve a larger volume of the stomach 
without jeopardizing long-term outcome. 
The SN is defined as a LN that directly drains a specific cancer. 
The concept of SN is based on the notion that non-SNs are un-
likely to contain cancer cells if the SN is cancer cell-free. In 1992, 
Morton et al.(3) demonstrated the concept of SN in a clinical study 
involving patients with malignant melanoma. Since then, the SN 
technique has been applied to the surgical management of a variety 
of cancers to avoid unnecessary lymphadenectomy.(4,5) 
With regard to gastric cancer, two Japanese studies were re-
ported around the outset of the 21st century. Hiratsuka et al.(2) 
reported that SN biopsy using ICG can be performed with a high 
success rate, and that the SN status can predict the LN status with 
a high degree of accuracy. Kitagawa et al.(1) reported their pre-
liminary data using intraoperative radiation technique and a gamma 
probe. 
Multi-Institutional Prospective Clinical Trials 
in Gastric Cancer Surgery
After the above two pioneering works in this area, several single 
institutional studies supported the validity of the SN concept for 
gastric cancer. In most of these studies, patients had T1 gastric 
cancer, and thus only a small number of patients reported in those 
studies had LN metastases. Moreover, the SN biopsy protocol var-
ies according to the surgeon. Therefore, not only single institutional 
studies with small number in different ways, but also studies with 
large number in a unified way have been conducted to evaluate the 
feasibility and clinical application of this technique. Under these 
circumstances, two multi-institutional prospective clinical trials; 
the Japan Clinical Oncology Group trial (JCOG0302) and the Japa-
nese Society for Sentinel Node Navigation Surgery (SNNS) trial, 
were conducted in Japan. The design and results of the two studies 
showed some rather large differences, as summarized in Table 1. 
The multicenter clinical trial, JCOG0302 (GCSSG-SNB, 
UMIN-CTR ID: C000000059), was designed to evaluate the fea-
sibility and accuracy of diagnosis using SN biopsy in T1 gastric 
cancer (Fig. 1). In other words, the feasibility of excluding lymph-
adenectomy during surgery for T1 gastric cancer was evaluated 
in patients with green nodes, representing SNs detected by ICG, 
which were considered cancer cell-free, by using intraoperative 
histopathological examination of frozen sections with hematoxylin-
eosin (H&E) staining. The primary endpoint was the false negative 
Table 1. Comparison between the JCOG0302 and the SNNS trials
JCOG SNNS
Primary endpoint False negative rate (based on intraoperative diagnosis) Detection sensitivity to metastases
Target Clinically T1N0 Clinically T1-2N0
Tracer ICG (subserosal injection in open surgery)
99mTc Tin colloid and isosulfan blue (submucosal 
injection using endoscopy)
Harvest Pick up within a time limit prior to gastrectomy with 
lymphadenectomy
Sampling in the surgical field and re-sampling in back 
table after lymphadenectomy
Intraoperative diagnosis Absolute requirement Desirable
Enrollment Intraoperative Before the day of operation
Participants 30 hospitals after learning period with 5 patients for each 
institution
12 hospitals with more than 30 experiences
JCOG = Japan Clinical Oncology Group; SNNS = Sentinel Node Navigation Surgery; ICG = indocyanine green.
Fig. 1. Trial scheme of the JCOG0302. Intraoperative detection of 
metastases in one plane of largest dimension of green nodes as SNs 
was performed using frozen sections and hematoxylin-eosin staining. 
Gastrectomy with lymphadenectomy was performed after SN biopsy. 
JCOG0302 = Japan Clinical Oncology Group trial; ICG = indocyanine 
green; SN = sentinel node.Problem of Sentinel Concept in Gastric Surgery
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rate (number of patients with an intraoperative negative SN biopsy/
number of patients confirmed later to have LN metastases). Pa-
tients with only intraoperative SN-positive biopsy were defined as 
“false positive” in the JCOG0302 trial. Caution should be exercised 
because patients with intraoperative SN-negative biopsy but SN-
positive histopathological examination of paraffin sections were 
defined as false negative in the trial although such SN biopsy was 
considered feasible based on the SN concept. The trial started in 
2004, however recruitment of patients was terminated midway be-
fore the goal because of the unexpected high false negative rate. 
Our pilot study adopted multi-planes for detection of metastases,(2) 
however, in the multicenter trial setting, only one plane of largest 
dimension of frozen section was adopted in the trial for conve-
nience. The planned learning period of 5 patients in each institution 
is probably an underestimation because the true number is con-
sidered to be 30 patients at present, as determined by the Japanese 
Society for SNNS. That is to say, the JCOG0302 was a trial to 
evaluate the feasibility of the current clinical setting, including sev-
eral issues on the SN concept as well as intraoperative histopatho-
logical examination using frozen sections and learning period. De-
tailed analysis of the false negative cases indicated that these issues 
adversely affected the outcome than expected (unpublished data). 
Another multicenter clinical trial was conducted by the Japanese 
Society for SNNS to evaluate the diagnostic accuracy of SNNS 
based on radio-guided method for LN metastases. The primary 
endpoint was the sensitivity of detection of metastases (number 
of patients with confirmed diagnosis of positive SN biopsy/num-
ber of patients with confirmed diagnosis of LN metastases). The 
SNNS trial differed from the JCOG0302 trial in that the entry 
criteria included both T1 and T2 gastric cancer, SN biopsy was 
performed by the dual tracer method (radioactivity was a manda-
tory requirement), SNs could be harvested in both surgical field 
and background table after gastrectomy, histopathological exami-
nation was performed on both frozen and paraffin sections, and 
only 12 well-experienced hospitals with more than 30 patients for 
learning period were included. The aim of the trial was to evaluate 
the SN concept in gastric cancer surgery based on the premise of 
substantial experience. The trial setting placed less emphasis on the 
accuracy of intraoperative histopathological examination of frozen 
sections and learning period, than the JCOG0302 trial. However, 
further steps are theoretically required for clinical application be-
cause detection of SN was unregulated before gastrectomy with 
lymphadenectomy. 
Matters of Debate
There are several matters of debate in performing the actual 
procedures, such as the type of tracer, the site of injection, how to 
detect and harvest, and how to detect metastatic SNs. These issues 
have to be addressed further to establish the best procedure. 
1. Type of tracer
The dye-guided method is safe, convenient, and cost-effective, 
whereas legal considerations and costs of radioactive substances 
limit the probe-guided method in general hospitals.(6,7) However, 
the dye-guided method has certain limitations, such as loss of vis-
ibility in dense fat and rapid transit of the dye, and these limitations 
are more critical in laparoscopic surgery. Subgroup analyses of 
meta-analyses showed that the combination of dye and radioactive 
colloid detection substances is better for detection.(8,9) Either way, 
adequate training is required as is evident.(10-12) 
ICG is a popular diagnostic reagent approved clinically,(13) and 
allergic reactions to ICG are fewer than those to blue dye such as 
isosulfan blue (Lymphazurin
TM).(14) As a tracer for SN biopsy, the 
injected ICG binds rapidly to albumin and is carried more specifi-
cally through the lymphatic vessels than indigo carmine or Evans 
Fig. 2. ICG-based novel techniques. 
Infrared imaging (B) allows easy visu-
alization of the LNs, which are other-
wise hardly recognized by ICG green 
color alone (A). The ICG fluorescence 
imaging (C) also allows separate vi-
sualization of LNs. Quotation from 
reference number 18 cited with minor 
alteration. ICG = indocyanine green; 
LN = lymph node.Miyashiro I
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blue.(15) Some ICG-based novel techniques such as infrared ray 
electronic endoscopy(16,17) and ICG fluorescence imaging(18-20) 
have been reported as convenient and reliable detection methods 
for clinical application of this technique using ICG dye (Fig. 2). 
Such newcomers could improve over time the cumbersome proce-
dure of combined tracers. 
2. Site of injection 
Theoretically, appropriate injection of tracer is essential for de-
tection of SNs. In other words, the site of injection (submucosal or 
subserosal) does not matter if all-round of the tumor is suffused by 
the injected tracer. Some have argued that the injection site of the 
tracer does not have to be limited to the submucosa.(21,22) Our ex-
perience also underwrites this argument (unpublished data). I guess 
that many surgeons mix up injection from luminal outside (so-called 
“subserosal injection”) with injection only into the subserosal tight 
space, which is unrealistic. 
The submucosal injection appears to be more reasonable than 
the subserosal injection in case of luminal organs probably due to 
accessibility by endoscopy. However, a point to remember is that 
the indications for SN should include T1 gastric cancer patients 
with ulceration, who are not suitable for endoscopic resection. Ap-
propriate injection of the tracer in such patients using endoscopy is 
difficult. On the other hand, subserosal injection into tumors on the 
lesser curve of the stomach is not easy and that is considered to be 
impractical in laparoscopic surgery. 
3. How to detect and harvest SNs 
The main methods used to detect and harvest SNs are nodes 
pickup biopsy(2) and lymphatic basin dissection.(23) Some have 
also proposed station instead of basin dissection.(24) Different 
from the pickup biopsy of a couple of nodes, basin dissection is a 
regional lymphadenectomy of one to two basins out of 5 basins of 
the stomach. It is obvious that finding true SNs is more difficult in 
the pickup method. Lee et al.(25) reported that a small number of 
SNs was found to be associated with false-negativity. However, the 
notion that basin dissection alone is sufficient for patients with T1 
gastric cancer who are not suitable for endoscopic resection, is in 
conflict with the golden standard of gastrectomy with lymphad-
enectomy. Adversely, if the above notion sticks to facts, it becomes 
unnecessary to detect and diagnose SNs because lymphatic flow 
only can guide us to the exact basin to dissect. 
In principle, however, basin dissection is in conflict with the SN 
concept, i.e., elimination of LN dissection. I believe we should stick 
to the main goal of the SN concept. 
4. Learning period
As already stated, a reasonable learning period is about 30 pa-
tients, as concluded from the survey conducted the Japanese Soci-
ety for SNNS. Lee et al.(26) reported that the learning period is 26. 
The learning period of just 5 patients for each institution (but not 
surgeon) advocated by the JCOG0302 trial is presumably an under-
estimation, and undoubtedly had a negative effect on the results of 
the trial. 
5. How to detect metastases intraoperatively
For clinical application of SN concept in gastric cancer surgery 
to avoid unnecessary lymphadenectomy, negative diagnosis of met-
astatic LN should be conducted intraoperatively before gastrectomy. 
Consequently, highly accurate intraoperative diagnostic methods 
are in great demand. Both the JCOG0302 trial and the SNNS trial 
indicated that intraoperative histopathological examination in one 
plane of largest dimension by frozen section with H&E staining is 
not highly accurate (unpublished data). 
Recently, a novel semi-automated molecular-based rapid di-
agnostic method for LN metastases has been developed in breast 
cancer using one-step nucleic acid amplification (OSNA), which 
requires approximately 30 minutes for final diagnosis.(27) A pro-
spective clinical trial of OSNA in four institutions including ours 
indicated that the method is feasible for intraoperative detection of 
LN metastases in patients with gastric cancer (paper in submission). 
Such new technology could overcome the difficulty of securing 
highly accurate intraoperative diagnosis. 
Conclusion
Now that we know what the problems are and how to avoid 
them, we can continue pursuing our goal.
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